These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 8699075

  • 1. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
    Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O.
    J Infect Dis; 1996 Aug; 174(2):404-7. PubMed ID: 8699075
    [Abstract] [Full Text] [Related]

  • 2. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
    Cohen OJ, Pantaleo G, Holodniy M, Schnittman S, Niu M, Graziosi C, Pavlakis GN, Lalezari J, Bartlett JA, Steigbigel RT.
    Proc Natl Acad Sci U S A; 1995 Jun 20; 92(13):6017-21. PubMed ID: 7597072
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
    Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O.
    J Infect Dis; 1997 May 20; 175(5):1051-5. PubMed ID: 9129065
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.
    Günthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, Mellors J, Gulick R, Frost SD, Brown AJ, Schleif W, Valentine F, Jonas L, Meibohm A, Ignacio CC, Isaacs R, Gamagami R, Emini E, Haase A, Richman DD, Wong JK.
    J Infect Dis; 2001 May 01; 183(9):1318-27. PubMed ID: 11294662
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV-1)-infected patients by serial lymph node aspiration.
    Bürgisser P, Spertini F, Weyrich-Suter C, Pagani JL, Meylan PR.
    J Infect Dis; 1997 May 01; 175(5):1202-5. PubMed ID: 9129086
    [Abstract] [Full Text] [Related]

  • 15. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA, Hughes MD, Liou SH, Katzenstein DA, Murphy R, Balfour HH, Para MF, Valdez H, Hammer SM, ACTG 303 Study Team.
    AIDS Res Hum Retroviruses; 2000 Sep 20; 16(14):1337-44. PubMed ID: 11018853
    [Abstract] [Full Text] [Related]

  • 16. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M.
    N Engl J Med; 1995 Dec 21; 333(25):1662-9. PubMed ID: 7477218
    [Abstract] [Full Text] [Related]

  • 17. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
    Mayers D, Bethel J, Wainberg MA, Weislow O, Schnittman S.
    J Infect Dis; 1998 Jun 21; 177(6):1730-3. PubMed ID: 9607859
    [Abstract] [Full Text] [Related]

  • 18. New developments in antiretroviral drug therapy for HIV-1 infections.
    Johnson VA.
    AIDS Clin Rev; 1998 Jun 21; ():305-46. PubMed ID: 7488558
    [No Abstract] [Full Text] [Related]

  • 19. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM, Chêne G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM.
    J Infect Dis; 1999 Aug 21; 180(2):351-8. PubMed ID: 10395849
    [Abstract] [Full Text] [Related]

  • 20. Therapy for human immunodeficiency virus infection -- what have we learned?
    Corey L, Holmes KK.
    N Engl J Med; 1996 Oct 10; 335(15):1142-4. PubMed ID: 8813046
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.